Analyzing WuXi PharmaTech (Cayman) (WX) and Intrexon (XON)
WuXi PharmaTech (Cayman) (NYSE: WX) and Intrexon (NYSE:XON) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
This is a summary of recent ratings and recommmendations for WuXi PharmaTech (Cayman) and Intrexon, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|WuXi PharmaTech (Cayman)||0||0||0||0||N/A|
This table compares WuXi PharmaTech (Cayman) and Intrexon’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|WuXi PharmaTech (Cayman)||7.52%||6.93%||4.67%|
Earnings & Valuation
This table compares WuXi PharmaTech (Cayman) and Intrexon’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|WuXi PharmaTech (Cayman)||N/A||N/A||N/A||$1.18||38.91|
|Intrexon||$190.93 million||8.26||-$186.61 million||($1.12)||-11.04|
WuXi PharmaTech (Cayman) has higher earnings, but lower revenue than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than WuXi PharmaTech (Cayman), indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
73.3% of Intrexon shares are owned by institutional investors. 55.1% of Intrexon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
About WuXi PharmaTech (Cayman)
WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Receive News & Ratings for WuXi PharmaTech (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi PharmaTech (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.